Alizadeh Leila, Salehi Leili
Department of Maternal and Child Health, Ardabil Branch, Islamic Azad University, Ardabil, IR Iran.
Department of Health Education and Promotion, School of Public Health, Alborz University of Medical Sciences, Karaj, IR Iran.
Iran Red Crescent Med J. 2016 Jan 27;18(1):e22761. doi: 10.5812/ircmj.22761. eCollection 2016 Jan.
Iron supplementation is a chief component in prenatal care, with the aim of preventing anemia; however, extreme maternal iron status may adversely affect the birth outcome. Given the negative consequences of high maternal iron concentrations on pregnancy outcomes, it seems that iron supplementation in women with high hemoglobin (Hb) should be limited.
The aim of this study was to examine the effect of iron supplementation on iron status markers in pregnant women with high Hb.
In a randomized, double-blind, placebo-controlled trial, 86 pregnant women with Hb > 13.2 g/dL and ferritin > 15 μg/l in the 16th - 20th week of pregnancy were randomized into experimental and control groups. From the 20th week until the end of pregnancy, the experimental group received one ferrous sulfate tablet containing 50 mg of elemental iron daily, while the control group received a placebo. Hb and ferritin levels at 37 - 39 weeks of pregnancy were evaluated and compared. In addition, after delivery the birth weight was measured in two groups and compared.
There were statistically significant differences between the two groups in Hb (p = 0/03) and ferritin (p = 0/04) levels at the end of pregnancy, but the incidence of anemia exhibited no difference in either group (p < 0/001). In addition, the mean of birth weight in experimental group and control group were 3391/56 ± 422, 3314/06 ± 341, respectively and it was not significant difference (p = 0.2).
Not using iron supplementation did not cause of anemia in women with Hb concentrations greater than 13.2 g/dL during pregnancy; thus, the systematic care and control of iron status markers without iron supplementation is recommended for these women.
铁补充剂是产前护理的主要组成部分,旨在预防贫血;然而,孕妇极端的铁状态可能会对分娩结局产生不利影响。鉴于母体高铁浓度对妊娠结局的负面影响,似乎血红蛋白(Hb)高的女性应限制铁补充剂的使用。
本研究旨在探讨铁补充剂对高Hb孕妇铁状态标志物的影响。
在一项随机、双盲、安慰剂对照试验中,将86例妊娠16至20周时Hb>13.2 g/dL且铁蛋白>15 μg/l的孕妇随机分为试验组和对照组。从第20周直到妊娠结束,试验组每天服用一片含50毫克元素铁的硫酸亚铁片,而对照组服用安慰剂。评估并比较妊娠37至39周时的Hb和铁蛋白水平。此外,分娩后测量两组的出生体重并进行比较。
妊娠结束时,两组的Hb(p = 0.03)和铁蛋白(p = 0.04)水平存在统计学显著差异,但两组贫血发生率无差异(p < 0.001)。此外,试验组和对照组的平均出生体重分别为3391.56±422、3314.06±341,差异不显著(p = 0.2)。
孕期Hb浓度大于13.2 g/dL的女性不使用铁补充剂不会导致贫血;因此,建议对这些女性在不补充铁的情况下系统护理和监测铁状态标志物。